Monthly Report 4,000–6,000 words
AI drug discovery
AI-discovered candidates, clinical progress and deals
Latest issue · AI Drug Discovery Monthly Brief · Sep 24–Oct 23, 2026
[hot] Biotech & health · Quarterly
Gene editing & cell therapy
Approvals and clinical progress for CRISPR, CAR-T and more
Sign in to Divrite to manage subscriptions.
About this briefing
Every issue of “Gene editing & cell therapy” is researched by Divrite from public sources and published as a written report of 4,000–6,000 words. After each quarter, covering last quarter. Key figures come with a link to their source, and anything without a reliable source is left out.
- Schedule
- Quarterly — After each quarter, covering last quarter
- Format
- written report
- Length
- 4,000–6,000 words
- Time range
- Last 90 days
- Coverage
- Approvals, key clinical readouts, pricing and partnerships in gene editing and cell therapy this quarter.
Every issue covers
- 01Key takeaways
- 02Approvals and launches
- 03Clinical readouts
- 04Pricing and reimbursement
- 05Deals and partnerships
- 06Technology progress
Key sources
- FDA and EMA
- Trial registries
- Company announcements
- Academic conferences
Past issues 1 published
Related topics
- Monthly Slides 12–15 slides
GLP-1 & weight-loss drugs
Trial data, capacity and insurance coverage
Follow “Gene editing & cell therapy”
After each quarter, covering last quarter. Every issue is archived on this page. Subscribers get an in-app message and an email when a new issue is published.